Is ATNM or KRRO more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Korro Bio N/A -114.26% -68.57%

Does the media favor ATNM or KRRO?

In the previous week, Korro Bio had 9 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 10 mentions for Korro Bio and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat Korro Bio's score of 0.07 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SPRB or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -123.53% -90.35% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to SPRB or ATNM?

In the previous week, Spruce Biosciences had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Spruce Biosciences and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat Spruce Biosciences' score of 0.58 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actinium Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HURA or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to HURA or ATNM?

In the previous week, TuHURA Biosciences had 5 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 6 mentions for TuHURA Biosciences and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat TuHURA Biosciences' score of 0.20 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ATNM or TNYA more profitable?

Tenaya Therapeutics' return on equity of -83.75% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Tenaya Therapeutics N/A -83.75% -66.53%

Is ATNM or ENGN more profitable?

enGene's return on equity of -27.97% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% enGene N/A -27.97% -22.65%

Does the media prefer ATNM or ENGN?

In the previous week, enGene had 18 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 19 mentions for enGene and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat enGene's score of 0.01 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Actinium Pharmaceuticals (ATNM) Competitors

$1.10 +0.02 (+1.85%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.10 0.00 (-0.09%)

As of 10/9/2026 07:30 PM Eastern

Compare

ATNM vs. KRRO, SPRB, HURA, TNYA, and ENGN

Should you buy Actinium Pharmaceuticals stock or one of its competitors? Actinium Pharmaceuticals's main competitors and comparable companies include Korro Bio (KRRO), Spruce Biosciences (SPRB), TuHURA Biosciences (HURA), Tenaya Therapeutics (TNYA), and enGene (ENGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Actinium Pharmaceuticals compare to Korro Bio?

Actinium Pharmaceuticals (NYSE:ATNM) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Actinium Pharmaceuticals' return on equity of -100.85% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Korro Bio	N/A	-114.26%	-68.57%

Actinium Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 354.55%. Korro Bio has a consensus price target of $16.50, indicating a potential upside of 62.40%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

In the previous week, Korro Bio had 9 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 10 mentions for Korro Bio and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat Korro Bio's score of 0.07 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Actinium Pharmaceuticals has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.99	-$48.82M	$0.36	3.06
Korro Bio	$6.39M	23.42	-$117.26M	-$10.00	N/A

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Actinium Pharmaceuticals has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.13, suggesting that its share price is 213% more volatile than the broader market.

Summary

Actinium Pharmaceuticals beats Korro Bio on 10 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Spruce Biosciences had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Spruce Biosciences and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat Spruce Biosciences' score of 0.58 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actinium Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spruce Biosciences has higher earnings, but lower revenue than Actinium Pharmaceuticals. Spruce Biosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	25.75	-$38.97M	-$39.78	N/A
Actinium Pharmaceuticals	$35.09M	0.99	-$48.82M	$0.36	3.06

Spruce Biosciences has a beta of 3.25, indicating that its share price is 225% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Actinium Pharmaceuticals' return on equity of -100.85% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Spruce Biosciences currently has a consensus target price of $158.33, suggesting a potential upside of 259.44%. Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 354.55%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Actinium Pharmaceuticals beats Spruce Biosciences on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Actinium Pharmaceuticals' return on equity of -100.85% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

TuHURA Biosciences currently has a consensus target price of $9.00, indicating a potential upside of 359.18%. Actinium Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 354.55%. Given TuHURA Biosciences' higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, TuHURA Biosciences had 5 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 6 mentions for TuHURA Biosciences and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat TuHURA Biosciences' score of 0.20 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences has higher earnings, but lower revenue than Actinium Pharmaceuticals. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Actinium Pharmaceuticals	$35.09M	0.99	-$48.82M	$0.36	3.06

TuHURA Biosciences has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Actinium Pharmaceuticals beats TuHURA Biosciences on 9 of the 14 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Tenaya Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Actinium Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 354.55%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 589.30%. Given Tenaya Therapeutics' higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Actinium Pharmaceuticals has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.99	-$48.82M	$0.36	3.06
Tenaya Therapeutics	$1.34M	97.47	-$90.60M	-$0.53	N/A

Actinium Pharmaceuticals has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market.

Tenaya Therapeutics' return on equity of -83.75% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

In the previous week, Actinium Pharmaceuticals and Actinium Pharmaceuticals both had 1 articles in the media. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat Tenaya Therapeutics' score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Positive
Tenaya Therapeutics	Neutral

Summary

Tenaya Therapeutics beats Actinium Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to enGene?

Actinium Pharmaceuticals (NYSE:ATNM) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

enGene's return on equity of -27.97% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
enGene	N/A	-27.97%	-22.65%

Actinium Pharmaceuticals has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.99	-$48.82M	$0.36	3.06
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

Actinium Pharmaceuticals has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, enGene has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

Actinium Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 354.55%. enGene has a consensus price target of $11.05, suggesting a potential upside of 538.47%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, enGene had 18 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 19 mentions for enGene and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat enGene's score of 0.01 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Actinium Pharmaceuticals and enGene tied by winning 7 of the 14 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATNM vs. The Competition

Export

Metric	Actinium Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$34.59M	$3.84B	$7.16B	$22.94B
Dividend Yield	N/A	3.66%	2.53%	3.72%
P/E Ratio	-0.79	13.42	274.15	28.60
Price / Sales	0.99	1,234.38	635.98	15.13
Price / Cash	N/A	116.56	76.38	37.72
Price / Book	0.84	17.17	11.21	4.72
Net Income	-$48.82M	-$22.69M	$3.50B	$1.07B
7 Day Performance	-5.98%	-1.33%	-0.90%	0.35%
1 Month Performance	-16.03%	-8.44%	-4.44%	-2.93%
1 Year Performance	-26.17%	14.02%	6.96%	9.26%

Actinium Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATNM Actinium Pharmaceuticals	2.6283 of 5 stars	$1.10 +1.9%	$5.00 +354.5%	-26.7%	$34.59M	$35.09M	N/A	25	News Coverage
KRRO Korro Bio	2.4468 of 5 stars	$9.56 +0.5%	$16.71 +74.8%	-78.3%	$140.04M	$2.38M	N/A	57	Positive News Analyst Forecast
SPRB Spruce Biosciences	3.1199 of 5 stars	$47.27 -0.5%	$158.33 +235.0%	-74.9%	$136.54M	$4.91M	N/A	8	Analyst Upgrade
HURA TuHURA Biosciences	1.8286 of 5 stars	$2.07 -1.0%	$9.00 +334.8%	-24.0%	$133.19M	N/A	N/A	22	Positive News
TNYA Tenaya Therapeutics	1.8784 of 5 stars	$0.59 +0.6%	$4.00 +574.4%	-71.3%	$132.25M	N/A	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ATNM) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. KRRO, SPRB, HURA, TNYA, and ENGN

How does Actinium Pharmaceuticals compare to Korro Bio?

Summary

How does Actinium Pharmaceuticals compare to Spruce Biosciences?

Summary

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

Summary

How does Actinium Pharmaceuticals compare to Tenaya Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. KRRO, SPRB, HURA, TNYA, and ENGN

How does Actinium Pharmaceuticals compare to Korro Bio?

Is ATNM or KRRO more profitable?

Do analysts rate ATNM or KRRO?

Does the media favor ATNM or KRRO?

Which has higher earnings and valuation, ATNM or KRRO?

Do institutionals and insiders hold more shares of ATNM or KRRO?

Which has more volatility and risk, ATNM or KRRO?

Summary

How does Actinium Pharmaceuticals compare to Spruce Biosciences?

Does the media refer more to SPRB or ATNM?

Which has better earnings & valuation, SPRB or ATNM?

Which has more volatility and risk, SPRB or ATNM?

Do institutionals & insiders have more ownership in SPRB or ATNM?

Is SPRB or ATNM more profitable?

Do analysts recommend SPRB or ATNM?

Summary

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

Is HURA or ATNM more profitable?

Do analysts rate HURA or ATNM?

Does the media refer more to HURA or ATNM?

Which has higher valuation & earnings, HURA or ATNM?

Which has more volatility and risk, HURA or ATNM?

Do insiders and institutionals believe in HURA or ATNM?

Summary

How does Actinium Pharmaceuticals compare to Tenaya Therapeutics?

Do insiders & institutionals hold more shares of ATNM or TNYA?

Do analysts rate ATNM or TNYA?

Which has better earnings and valuation, ATNM or TNYA?

Which has more volatility & risk, ATNM or TNYA?

Is ATNM or TNYA more profitable?

Does the media prefer ATNM or TNYA?

Summary

How does Actinium Pharmaceuticals compare to enGene?

Is ATNM or ENGN more profitable?

Which has better valuation & earnings, ATNM or ENGN?

Which has more risk & volatility, ATNM or ENGN?

Do analysts prefer ATNM or ENGN?

Does the media prefer ATNM or ENGN?

Do institutionals and insiders hold more shares of ATNM or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools